Drug Profile
Research programme: immunecheckpoint inhibitor combination therapy - VCN Biosciences
Latest Information Update: 16 Mar 2022
Price :
$50
*
At a glance
- Originator VCN Biosciences
- Class Gene therapies; Oncolytic viruses
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 11 Mar 2022 VCN Biosciences has been acquired by Synthetic Biologics
- 28 Feb 2021 No recent reports of development identified for preclinical development in Cancer in Spain (Parenteral, Injection)
- 24 Jan 2017 Preclinical trials in Cancer in Spain (Parenteral)